Difference between revisions of "Team:Oxford"
Maxtaylor273 (Talk | contribs) |
|||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 24: | Line 24: | ||
<header class="py-5 background-img parent" style="height: 600px"> | <header class="py-5 background-img parent" style="height: 600px"> | ||
<a href="#n1"style="text-decoration : none; color:white;"> | <a href="#n1"style="text-decoration : none; color:white;"> | ||
| − | <div class="child background-img" style="background-image: url('https://static.igem.org/mediawiki/2018/ | + | <div class="child background-img" style="background-image: url('https://static.igem.org/mediawiki/2018/1/1a/T--Oxford--header-three.jpg'); background-size: cover;"> |
<h1 class="header-text" style="text-decoration : none; color:white !important;">Revolutionising Immunosuppressants</h1> | <h1 class="header-text" style="text-decoration : none; color:white !important;">Revolutionising Immunosuppressants</h1> | ||
</div> | </div> | ||
| Line 35: | Line 35: | ||
<div class=".col-md-8 .offset-md-2"> | <div class=".col-md-8 .offset-md-2"> | ||
| − | + | <style type="text/css"> | |
| + | .tftable {font-size:17px;color:#333333;width:100%;border-width: 1px;border-color: #729ea5;border-collapse: collapse;} | ||
| + | .tftable th {font-size:17px;background-color:#E5FCE2;border-width: 1px;padding: 8px;border-style: solid;border-color: #729ea5;text-align:left;text-align:center;} | ||
| + | .tftable tr {background-color:#FFFFFF;} | ||
| + | .tftable td {font-size:17px;border-width: 1px;padding: 8px;border-style: solid;border-color: #729ea5; text-align:center;} | ||
| + | .tftable tr:hover {background-color:#F2F2F2;} | ||
| + | h3 { | ||
| + | text-decoration:; | ||
| + | } | ||
| + | </style> | ||
| + | |||
| + | <table class="tftable" border="1"> | ||
| + | <center> | ||
<tr><th>Achievement</th><th>Award</th></tr> | <tr><th>Achievement</th><th>Award</th></tr> | ||
<tr><td>Winners</td><td>Therapeutics Track</td></tr> | <tr><td>Winners</td><td>Therapeutics Track</td></tr> | ||
| Line 41: | Line 53: | ||
<tr><td>Nominated</td><td>Best Entrepreneurship</td></tr> | <tr><td>Nominated</td><td>Best Entrepreneurship</td></tr> | ||
</td><td>Nominated</td><td>Best Wiki</td></tr> | </td><td>Nominated</td><td>Best Wiki</td></tr> | ||
| − | </td><td>Gold</td><td> | + | </td><td>Gold</td><td>Medal</td></tr> |
| − | </ | + | </center></table> |
<br> | <br> | ||
| − | |||
<h2>Abstract<br></h2> | <h2>Abstract<br></h2> | ||
<p class="lead"><br>Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of the intestine. The condition is associated with an imbalance in immune cell populations, notably Th17 and Treg. Existing immunosuppressive therapies, when successful, often elicit systemic side effects and require frequent readministration. Our solution is to develop a probiotic strain that restores the Th17/Treg cell balance via secretion of IL-10 in response to nitric oxide in the intestinal lumen. Overshoot is prevented by an adenine riboswitch-sRNA construct which responds to extracellular adenosine, an indicator of the Treg cell population. Integration of separate stimuli in a dual feedback loop enables a more dynamic, robust response to the immune state of the body. Various features have been incorporated to maximise biological safety, including an inducible kill switch system. We believe our design offers a non-invasive, self-tuning therapeutic for IBD, with potential to replace conventional immunosuppressants in the treatment of gastrointestinal autoimmune disorders. </p> | <p class="lead"><br>Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of the intestine. The condition is associated with an imbalance in immune cell populations, notably Th17 and Treg. Existing immunosuppressive therapies, when successful, often elicit systemic side effects and require frequent readministration. Our solution is to develop a probiotic strain that restores the Th17/Treg cell balance via secretion of IL-10 in response to nitric oxide in the intestinal lumen. Overshoot is prevented by an adenine riboswitch-sRNA construct which responds to extracellular adenosine, an indicator of the Treg cell population. Integration of separate stimuli in a dual feedback loop enables a more dynamic, robust response to the immune state of the body. Various features have been incorporated to maximise biological safety, including an inducible kill switch system. We believe our design offers a non-invasive, self-tuning therapeutic for IBD, with potential to replace conventional immunosuppressants in the treatment of gastrointestinal autoimmune disorders. </p> | ||
Latest revision as of 03:02, 8 December 2018
Revolutionising Immunosuppressants
| Achievement | Award |
|---|---|
| Winners | Therapeutics Track |
| Nominated | Best Human Practices |
| Nominated | Best Entrepreneurship | Nominated | Best Wiki | Gold | Medal |
Abstract
Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of the intestine. The condition is associated with an imbalance in immune cell populations, notably Th17 and Treg. Existing immunosuppressive therapies, when successful, often elicit systemic side effects and require frequent readministration. Our solution is to develop a probiotic strain that restores the Th17/Treg cell balance via secretion of IL-10 in response to nitric oxide in the intestinal lumen. Overshoot is prevented by an adenine riboswitch-sRNA construct which responds to extracellular adenosine, an indicator of the Treg cell population. Integration of separate stimuli in a dual feedback loop enables a more dynamic, robust response to the immune state of the body. Various features have been incorporated to maximise biological safety, including an inducible kill switch system. We believe our design offers a non-invasive, self-tuning therapeutic for IBD, with potential to replace conventional immunosuppressants in the treatment of gastrointestinal autoimmune disorders.